A media release issued yesterday by Progenics Pharmaceuticals states that the investigational imaging agent 18F-DCFPyL changed physician behavior in the management of biochemically recurrent prostate cancer in > 65 percent of patients. … READ MORE …
Filed under: Uncategorized | Tagged: 18F-DCFPyL, biochemical, change, CT, imaging, Management, PET, recurrence, scan | Leave a comment »
Depression is relatively common among men with prostate cancer. Indeed, it may be a lot more common than we can currently document. … READ MORE …
Filed under: Uncategorized | Tagged: ADT, androgen, cancer, depression, deprivation, prostae, risk | 3 Comments »
In this week’s Journal of Clinical Oncology, there is a full-text article in the “Comments and Controversies” section entitled … READ MORE …
Filed under: Uncategorized | Tagged: DNA, genetic, genomic, germline, test | 2 Comments »
In his latest epistle on living with cancer on MedPage Today, Howard Wolinsky addresses what he has come to understand is a very sensitive topic. … READ MORE …
Filed under: Uncategorized | Tagged: battle, cancer, fight, survivor, war, warrior | 5 Comments »
Some data presented a few weeks ago at the annual meeting of the European Association for Urology appear to have surprised not only the study’s authors, but pretty much everyone else as well. … READ MORE …
Filed under: Uncategorized | Tagged: low risk, replacement, serum, surgery, testosterone, TRT | 6 Comments »
A newly published article in this month’s Journal of Urology has suggested that being exposed to Agent Orange and getting prostate cancer comes with better overall survival data than if one gets prostate cancer some other way. … READ MORE …
Filed under: Uncategorized | Tagged: ADT, agent, androgen, cancer-specific, deprivation, exposure, Orange, prostate, survival | 2 Comments »
The issue of whether routine use of dietary supplements has any meaningful therapeutic benefit has long been a controversial issue (and we don’t expect that to change as a result of what appears below, but …) … READ MORE …
Filed under: Uncategorized | Tagged: diet, dietary, mortality, risk, supplement | 1 Comment »
According to a report on the US Food and Drug Administration (FDA) web site, the FDA has just approved the “finger-prick” Sangia Total PSA blood test developed by OPKO Diagnostics. … READ MORE …
Filed under: Uncategorized | Tagged: finger-prick, OPKO, PSA, Sangia | 3 Comments »
So some readers will already have seen the article in today’s New York Times entitled “Cancer’s trick for dodging the immune system“. … READ MORE …
Filed under: Uncategorized | Tagged: cure, exosome, laboratory, mice, PD-L1 | 4 Comments »
The Restore study is a new, NIH/NCI-funded, clinical trial designed to explore what will help gay, bisexual, and other men who have sex with men (collectively, MsM) to recover urinary, sexual, and erectile function after treatment for prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: bisexual, erectile, function, gay, MSM, rehabilitation, restoration, sexual, urinary | 6 Comments »
With apologies to the Bard of Avon and his character Hamlet, the above-misquoted Prince of Denmark, we bring to your attention the most recent article by our good friend Howard Wolinsky on issues related to prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: Diagnosis, digital, DRE, examintatin, rectal, risk | 12 Comments »
We have heard a lot about treatment with checkpoint inhibitors over the past two or three years. When they work well, they can work very well indeed, but these drugs come with significant risk for side effects, and some of those side effects can be very serious. … READ MORE …
Filed under: Uncategorized | Tagged: checkpoint, CTLA4, immunotherapy, inhibition, PD-1, PD-L1, risk | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 